We are live on ! Find out more
EIGR

Eiger BioPharmaceuticals, Inc.
EIGR

Delisted

EIGR was delisted on the 10th of April, 2024.

Back to rankings

66 hedge funds and large institutions have $248M invested in Eiger BioPharmaceuticals, Inc. in 2014 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 9

102% more capital invested

Capital invested by funds: $123M → $248M (+$125M)

47% more funds holding

Funds holding: 45 → 66 (+21)

27% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 11

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
66
Holders Change
+21
Holders Change %
+46.67%
% of All Funds
1.76%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
30
Increased
14
Reduced
11
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EAM
Eagle Asset Management
Florida
+$7.55M
2
FCM
Frontier Capital Management
Massachusetts
+$5.03M
3
EAM
EverPoint Asset Management
Connecticut
+$3.87M
4
BFA
BlackRock Fund Advisors
California
+$3.53M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$1.26M

Top Sellers

Rank Fund Capital Flow
1
TCM
Tekla Capital Management
Massachusetts
-$4.7M
2
MAM
MPM Asset Management
Massachusetts
-$3.44M
3
VAM
Visium Asset Management
New York
-$3.34M
4
PHS
PFM Health Sciences
California
-$1.62M
5
Axa
Axa
France
-$1.18M
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$1.07M – – –
Millennium Management
27
Millennium Management
New York
$852K +$563K +97 New
OPPM
28
Opus Point Partners Management
New York
$828K +$546K +94 New
TC
29
TFS Capital
Pennsylvania
$821K +$232K +40 +75%
TD Asset Management
30
TD Asset Management
Ontario, Canada
$814K +$34.8K +6 +7%
RCM
31
RA Capital Management
Massachusetts
$799K +$528K +91 New
GTC
32
Ghost Tree Capital
New York
$781K +$517K +89 New
PC
33
Polar Capital
United Kingdom
$680K +$447K +77 New
PVI
34
Pura Vida Investments
New York
$656K +$435K +75 New
Two Sigma Investments
35
Two Sigma Investments
New York
$442K +$290K +50 New
Renaissance Technologies
36
Renaissance Technologies
New York
$422K +$279K +48 New
D.E. Shaw & Co
37
D.E. Shaw & Co
New York
$375K +$5.8K +1 +2%
Deutsche Bank
38
Deutsche Bank
Germany
$375K +$133K +23 +115%
BIT
39
BlackRock Institutional Trust
California
$364K – – –
RJA
40
Raymond James & Associates
Florida
$355K +$232K +40 New
Northern Trust
41
Northern Trust
Illinois
$329K +$17.4K +3 +9%
ProShare Advisors
42
ProShare Advisors
Maryland
$301K +$197K +34 New
BIM
43
Baldwin Investment Management
Pennsylvania
$285K – – –
V
44
Veritable
Delaware
$285K – – –
Goldman Sachs
45
Goldman Sachs
New York
$279K +$186K +32 New
MCM
46
Manchester Capital Management
Vermont
$263K – – –
AL
47
Airain Ltd
Guernsey
$252K +$168K +29 New
ARTA
48
A.R.T. Advisors
New York
$223K +$145K +25 New
Connor, Clark & Lunn Investment Management (CC&L)
49
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$213K +$139K +24 New
PIM
50
Partner Investment Management
California
$201K -$40.6K -7 -23%
1
2
3 4

EIGR Hedge Fund Activity: Q4 2014 in Review

66 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q4 2014, worth a combined $248M — up 102% from $123M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new EIGR positions and 9 closed out — a net gain of 21 holders — while 14 added to existing stakes and 11 trimmed.

The largest buyer was Eagle Asset Management, adding an estimated $7.55M. The largest seller was Tekla Capital Management, cutting an estimated $4.7M.

  • 66 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q4 2014, up from 45 in Q3 2014.
  • Funds reported $248M of Eiger BioPharmaceuticals, Inc. stock for Q4 2014, up 102% quarter-over-quarter.
  • 30 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q4 2014 and 9 closed out, a net change of +21 holders.
  • The largest Eiger BioPharmaceuticals, Inc. buyer in Q4 2014 was Eagle Asset Management, an estimated $7.55M added.
  • The largest Eiger BioPharmaceuticals, Inc. seller in Q4 2014 was Tekla Capital Management, an estimated $4.7M sold.

Based on aggregated 13F filings for Q4 2014.